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1. Introduction 
Slavin et al. in [1976], were the first to found that rejection of skin and heart allograft was 
greatly delayed in rodents treated with Total Lymphoid Irradiation (TLI). Since 1980, the 
immunosupression of TLI has been applied in transplants and autoimmune diseases. 
However, the development of immunosuppressive drugs decreased the use of radiotherapy 
for immunosuppressive finality except for the use of total body irradiation (TBI) or TLI  as  
myeloablative treatment before bone marrow transplantation  
The mechanism by which TLI-treated patients have a graft prolongation is not entirely 
understood. During many years of its use many changes has been observed specially in 
lymphocytes counts. The majority of the studies, however, were done without modern 
techniques to characterize the fate of different subtypes of lymphocytes and  is difficult to 
compare the results. The majority of the studies has been done in vitro and in regimes using 
TBI and bone marrow transplants. There is some evidence that suppressor T-cells might be 
involved in the long term maintenance of allografts in these patients [Gray et al, 1989]. TLI 
provokes a more pronounced impairment of T-dependent immunological functions, as 
measured with phytohemaglutinin- (PHA), concanavalin A- (Con A), and pokeveed-
induced (PWM) blastogenesis than does conventional immunosuppression.  The more 
profound changes in the balance between T helper and T suppressor cells after TLI are also 
associated with a more pronounced suppressor cell activity, as measured with different 
functional suppressor cell assays. [Fergunson et al, 1981; Waer et al, 1987]. The TLI seems to 
produce an “amnesic state” and the autoantigens cannot be recognized by the host anymore. 
In the past, radiation therapy had traditionally been viewed as immunosuppressive (Cole, 
1986; James et al., 1989; Wasserman et al., 1989). Lymphocyte radiosensitivity is well 
established and remains the dominant explanation for this effect. However, substantial 
evidence suggests more varied effects of radiation on the immune system, prompting the re-
characterization of radiation as ‘immunomodulatory’ rather than immunosuppressive 
(McBride et al., 2004).  
Ionising radiation induces diverse effects on cell survival, apoptosis, proliferation and 
differentiation depending on the dosage and target cell (Jonathan et al. 1999). High dose of  
radiation often results in massive DNA damage that involves double-strand breaks and 
subsequent cell death. Low dose of irradiation induces reactive oxygen species (ROS) and 
the activation of specific intracellular signaling pathways and transcription factors leading 
to proliferation and differentiation of target cells (Kasid et al. 1996, Lander et al. 1997, Finkel 
1998). Therefore, irradiation can modulate immune response via its variable effects on immune 
cell survival and differentiation (Shankar et al. 1999, Rho et al. 2004, Liu 2007, Shan et al.2007).  
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The immune system responds to ionizing  radiation with distinct characteristics depending 
on multiple factors such as dose and dose rate, tissue and cell types. Overall, immune cells 
are susceptible to radiation-induced damage and readily undergo apoptosis in response to 
small doses of radiation. Cellular apoptosis is critically regulated by various intracellular 
and extracellular signaling mechanisms. CD95 (Apo-1/Fas) is a homotrimeric tumour 
necrosis factor receptor (TNFR) family member characterised by the presence of a death 
domain in its cytoplasmic tail. CD95-mediated apoptosis is an important process with 
enormous physiological and pathophysiological impact and cell-type-specific features. 
CD95 molecules have been implicated in the maintenance of self-tolerance and T-cell 
homeostasis by transmitting apoptotic signals to repeatedly activated antigen-specific T 
cells, as well as to antigen-presenting dendritic cells (DCs) and activated B cells. (Schu¨ tze et 
al. 2008).  For example, It has been described that Treg maintain immunological tolerance by 
suppression of autoreactive T cells but it was also  shown that low dose total body 
irradiation (LTBI) selectively decreased the proportion and absolute number of Treg and 
enhanced antitumor immunity in murine model. It occurs because Treg displaying much 
higher apoptotic baseline and apoptosis-related proteins are more radiosensitive than its 
effector counterpart CD4pCD257T cells ( Mendge et al, 2011) An  important finding to  help 
explain the immune ‘stimulating’ effect of low dose irradiation is the differential impact on 
Treg vs. CD4þ CD257 cell population. These relevant findings appoint to the hypotheses 
that the   net balance for the immune system may be a relative decrease in Treg-mediated 
suppression and a net increase in effector T cell activity. Similar effect was confirmed in in-
vivo that LTBI is a very attractive adjuvant strategy to enhance overall cancer 
immunotherapy or vaccine responses (Liu et al.2010). Other possible  mechanisms of 
immune enhancement are elimination of suppressor cells as Treg and myeloid suppressor 
cells and augmentation of the immune response including natural killer (NK) cells, B cells 
and T cells activation, costimulatory molecules upregulation, IFNg and IL-2 production and 
release, and enhanced proliferative activity of lymphocytes to mitogenic stimuli ( Belka et al, 
1999; Hashimoto et al, 1999; Safwat 2000a; 2000b; Liu et al, 2001; Kipnis et al, 2004; Jin et al, 
2007; Shan et al, 2007) 
Although the effects of radiation on the survival of lymphocytes have been extensively 
studied in vitro, a correlation of the frequency of radiation-induced apoptosis in human 
peripheral blood lymphocytes during TLI have not previously been performed. In 2008 we 
published the clinical results of a protocol using TLI plus immunosuppressive agents to 
prevent recurrence after renal transplant in patients with focal and segmental 
glomerulosclerosis (FSGS) (Villar et al, 2008). This disease presents with early recurrence 
after renal transplants and an involvement of the immune system has  been implicated in its 
pathogenesis.  During the study the purpose was also to investigate the changes in 
peripheral blood monocyte and lymphocyte subpopulations and the role of the in vivo 
induction of apoptosis in patients undergoing TLI pre renal transplant (TX) (unpublished 
data). It was a very rare opportunity to study in vivo  the immunosuppressant effect  caused 
by TLI during each week of the treatement  in patients that had not received any 
immunosuppressive drug or chemotherapy before.  We studied 9 patients and they were 
treated with aggressive immunosuppressive treatment associating TLI with the drugs 
mycophenolate mofetil (MMF), prednisone (PRED) and cyclosporine (CsA) commonly used 
in conventional immunosuppressive treatments. TLI were performed as described in Villar 
et al, 2008. Immunophenotyped peripheral blood T and B lymphocyte subsets and 
monocytes were performed before treatment (control) and followed during each week of 
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TLI (after each 9 Gy), on TX´s day and after TX (30, 60 and 90 days) using flow cytometry. 
The percentages of T-helper, T-suppressor, B-lymphocytes and monocytes/macrophages 
cells, were determined on the cells in the lymphogate. Mitogen stimulation tests in 
lymphocytes culture using phytohemaglutinin (PHA) and pokeweed mitogen (PWM) were 
performed before and after completion of TLI, at the TX day and at 1 month interval up to 
three months post-transplantation. 
1.1 Isolation of lymphocytes and detection of apoptosis  
The in vivo radiation-induced apoptosis in lymphocytes was investigated in blood samples 
of 9 patients before TLI, pre and pos-hemodyalisis (controls 1 and 2) and 6h and 24h after 
the first and the second fraction of TLI and 6h after each 9 Gy until the end of TLI. The 
observation of apoptosis on freshly blood samples (2 patients) were insignificant then in the 
others (7 patients), we decided to observe  the commitment to apoptosis of the lymphocytes 
irradiated in vivo after 72h in cell culture with and without mitogen (PHA) using an ex vivo 
test. After the cells were kept in culture they were assessed for binding of Annexin by 
resuspending 2 x105 cel/100µl and subsequently by incubating with 10µl Annexin V-FITC 
for 30min. In order to distinguish between apoptotic (Annexin V+/PI-) and secondary 
necrotic (Annexin V +/PI+) cells, 10µl of propidiun iodeto (PI) (2µg/ml) was also added 
before analyzing on a Coulter Epics XL-MCL flow cytometer. Two-colour flow-cytometric 
analyses were performed on a FACSort. A gate was put on Annexin V + (green) cells and a 
backgating performed on the scatter plot in order to discriminate optimally platelets and 
debris from smaller apoptotic cells with exclusion of monocytes (increased side scatter). In 
cells with a damaged membrane PI cannot be excluded anymore and a red fluorescent 
signal was observed indicating secondary necrotic cells. The results were expressed as 
percentage of apoptotic cells in 10.000 cells counted in the pre-determined window.  All the 
results were expressed as the percentage of the pre-treatment value. Statistical analysis was 
performed comparing the values before and after treatment (Friedman`s ANOVA – p ≤ 
0.05). We observed significant reduction of all parameters analysed after treatment. 
Leukocytes decreased 55%, lymphocytes had a reduction of 60%, 70 % and 97 % for 
CD3/CD4, CD8 and CD19, respectively, at the transplant’s day (p<0,05) The statistical 
analysis showed a significant decrease since the first week of TLI (p<0,05). The steep 
decrease for T cells was not significantly different between CD4 and CD8, but the decrease 
of B-cells was significantly more important than T-cells (fig.1). The decrease observed in 
CD14 cells was not significant (p=0,569). Lymphocytes proliferative activity decrease 60% 
(with PHA) and 67% (with PWM) after TLI. The PWM response was less expressive (p = 
0,09), statistical analysis showed reduction significantly maintained after TX only with PHA 
(p=0,009) (fig 2,3).   
There was significant increase of apoptosis in vivo in peripheral blood lymphocytes (PBL) in 
the beginning of TLI, (6h after first fraction of TLI) and necrosis at the end of TLI (10 and 15 
fractions of TLI) (fig. 4,5). The phenomenon (apoptosis) was significantly increased by PHA 
stimulus (fig.6). 
In our experience TLI provide important immunosuppresion with a significant fall in T and 
B lymphocytes and functional response to PHA. The B lymphocytes were the more 
radiosensitive and the monocyte the most radioresistant cells. No significant differences 
between T-helper and T-supressor/cytotoxic cells were observed.TLI induced significant 
increase of apoptosis in vivo in PBL after low doses and necrosis after high doses of TLI.  
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Fig. 1. Response of CD3, CD4, CD8, CD19 lymphocytes during radiotherapy and after 
transplant. The results were normalized to the values obtained before the treatment and 
plotted against the equivalent period of evaluation. A mean time-response curve resulting 
from statistical analyse to the data of all patients (mean A). Individual patients results are 
indicated on the figures 
 
 
Fig. 2. Response of monocytes (CD14) with dose (Gy) in the nine (9) patients. The results 
were normalised to the values obtained before the start of the TLI and plotted against the 
equivalent period of the irradiation (first to fourth week). 
CD3 
5tli 10tli 15tli 20tli Tx 30d 60d 90d 
0 
50 
100
150
#1 
#2 
#3 
#4 
#5 
#7 
#8 
#9 
mean A 
CD4
5tli 10tli 15tli 20tli Tx 30d 60d 90d 
0 
50
100 
150 
#1 
#2 
#3 
#4 
#5 
#6 
#7 
#8 
#9 
mean A 
CD8 
5tli 10tli 15tli 20tli Tx 30d 60d 90d 
0 
50 
100 
150 
#1 
#2 
#3 
#4 
#5 
#6 
#7 
#8 
#9 
mean A
 CD19 
5tli 10tli15tli 20tli Tx 30d60d 90d 
0 
50 
100
150
#1 
#2 
#3 
#4 
#5 
#6 
#7 
#8 
#9 
mean A
Periods of  protocol  
Normalised number cells
MONOCYTES 
0 9 18 27 36 
0 
20 
40 
60 
80 
100 
120 
CD14 
DOSE (Gy) 
N
o
rm
a
li
s
e
d
 n
u
m
b
e
r 
c
e
ll
s
 
www.intechopen.com
 
Radiotherapy and Immunity – A Mini Review 
 
389 
 
Fig. 3. Lymphoproliferative activity of 9 patients during the periods of protocol: control, 
after TLI  (day of TX), 30, 60 and 90 days after TX. PHA =  lymphocytes culture with 
phitohemaglutinin mitogen stimulation. PWM =  lymphocytes culture with pokeweed 
mitogen stimulation 
 
 
Fig. 4. Percentagem of apoptotic cells (Annexin+) observed in culture of lymphocytes 
without PHA. Results of controls (normal subjects, patients pre and post-dialysis and before 
TLI) , patients during TLI and on TX´s day 
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Fig. 5. Percentagem of necrotic cells (Pi +) observed in culture of lymphocytes without PHA. 
Results of controls (normal subjects, patients pre and post-dialysis and before TLI) , patients 
during TLI and on TX´s day. Necrotics cells increased at the end of TLI 
 
 
Fig. 6. Comparative analyse of percentagem of apoptotics cells observed in the periods of 6h 
and 24h after first fraction of TLI in culture of lymphocites with and without PHA.The 
percentagem of apoptosis was higher in the presence of PHA 
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2. Mini review 
Lymphocyte radiosensitivity is well established and remains the dominant explanation for 
the immunosuppressive  effect of radiotherapy. However, substantial evidence suggests 
more varied effects of radiation on the immune system, prompting the re-characterization of 
radiation as ‘immunomodulatory’ rather than immunosuppressive (McBride et al., 2004). 
The effect of radiotherapy in microenviroment, cytokines, gene expressions and the 
importance of the dose in the immunossuprressive effect has emerging as new and 
important concepts. The use of the immunomodulatory effect of radiation in oncology has 
been pointed as a new perspective and its participation has again increasing in transplants 
tolerance and in treatment of autoimmune diseases. In the next pages we describe the new 
and important concepts recently acquired in radiotherapy and immunity 
2.1 The role of radiation 
2.1.1 Immunomodulatory effects of radiation 
Increased expression of proinflammatory cytokines, including TNF-a and IL-1b following 
radiation has been reported by some authors (Hallahan et al.,1989; Ishihara et al., 1995; 
Nemoto et al., 1995). These observations suggest a potential role for radiation in signaling 
‘danger’ and, perhaps, in the activation of antigen presenting cells (McBride et al., 2004). 
However, studies aimed at determining the effects of radiation on antigen-presenting cell 
phenotype, cytokine expression and function have been contradictory. While alterations in 
dendritic cells (DC) phenotype have been demonstrated infrequently (Cao et al.,2004), a 
number of investigators have noted changes in the cytokine secretory profile and function of 
DCs following irradiation. For example, Shigematsu et al. (2007), reported enhanced 
expression of IL-2, IL-12 and IFN-g by irradiated DCs and  it was correlated with greater T-
cell proliferation  compared to non-irradiated DCs. In contrast, Merrick et al. (2005) reported 
decreased IL-12 production and impaired naive T-cell priming by irradiated compared to 
non-irradiated DCs. These contradictory findings may be attributable to the different 
irradiation strategies and models utilized in these studies. The effect of radiation on DC 
antigen presentation also remains controversial with a number of studies suggesting 
significant modulation of, or no effect on, T-cell stimulatory capacity. Interestingly, Liao et 
al. (2004) reported impaired T-cell priming against endogenously processed antigen and 
enhanced priming against exogenous peptide pointing to a more complex interplay between 
radiation and DC function. A number of factors may explain why the consistent 
characterization of immune responses to radiation remains elusive including differences in 
radiosensitivity or reactivity of different cell and tissue types, and dose-dependent effects. 
For example, the dose effect  has been explored in a number of studies, some of which 
suggesting  that lower doses of radiation have a greater potential to enhance immune 
responses (Hashimoto et al., 1999; Cao et al., 2002; Shigematsu et al., 2007)  
3. Irradiation and transplants 
Recently, the approach of combined organ and hematopoietic cell transplantation has been 
successfully applied to tolerance induction in humans (Fudaba el al., 2006; Scandling et al., 
2008; Kawai et al., 2008). Conditioning regimens used to achieve mixed chimerism and 
tolerance include lethal and sublethal total body irradiation (TBI) with or without thymic 
irradiation and anti-T cell antibodies (Ildstad & Sachs 1984; Kawai et al., 2002; Stykes 2001), 
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TLI with and without anti-T cell antibodies (Slavin et al., 1976; Slavin et al., 1978; Slavin et al, 
1977; Scandling et al., 2008 ;Hayamizu et al, 1999; Lan et al, 2000; Higuchi et al, 2002), 
costimulatory blockade with or without rapamycin therapy or cytoreduction (Wekerle et al, 
2000; Durhan et al, 2000; Lambert et al., 2002;Graca et al., 2006), injection of naturally 
occurring CD4+CD25+ Treg (nTreg) cells combined with radiation cytoreduction (Golshayn 
et al., 2007; Wood & Sakaguchi, 2003), and chemical cytoreduction combined with thymic 
irradiation, and anti-T cell antibodies (Fudaba et al, 2006; Kawai et al 2008,). 
Although central and peripheral clonal deletion in chimeras can explain the lack of 
reactivity of host immune cells to donor alloantigens (Stikes 2001; Wekerle et al, 1998), host 
regulatory T cells that remain after cytoreduction or that are injected after cytoreduction can 
also play an important role in the engraftment of the donor organ and hematopoietic cells 
(Higushi 2002, Golshayn et al, 2007; Wood & Sakaguchi 2003).  
In the mixed chimera and tolerance induction model with TLI, anti-thymocyte serum 
(ATS),and bone marrow transplantation, tolerance is dependent on the residual host natural 
killer (NK) T cells . However,CD4 regulatory T cells, (Tregs) and   nTregs  induced from 
CD4+CD25- T cell precursors (iTregs) have been shown to play an important role in 
promoting tolerance to allografts in both chimeric and non-chimeric mouse models 
(Lambert et al., 2002,Chai et al, 2005,Graca et al., 2002, Sakaguchi, 2005, Kang et al, 2007). 
Nador et al, 2010 has been studying   the role of residual host Tregs in the mixed chimera 
model using TLI and ATS conditioning. They demonstrated the  requirement for host Tregs 
selectively depleting these cells pretransplant with a single injection of anti-CD25 mAb. The 
experiment results showed that deficiency in either NK T cell or Tregs prevents chimerism 
and tolerance in the TLI and ATS model. This lymphodepletive-conditioning regimen 
facilitated tolerance by altering the balance of host T cell subsets to markedly favor the NKT 
cells and Tregs over alloreactive host naïve (CD62LhiCD44lo) T cells. Therefore, the changes 
in the balance of regulatory and naïve T cell subsets and their contributions to graft 
acceptance or rejection using a TLI and ATS conditioning regimen is the responsible to 
induce mixed chimerism and tolerance after combined heart and bone marrow 
transplantation (Hayamizu et al.,  1999; Lan et al., 2000; Higuchi et al., 2002). 
It was demonstrated that one day after the completion of TLI and ATS conditioning (time 
point of donor bone marrow infusion) there was a marked increase in the ratio of CD4+ 
CD25+Foxp3+ Treg cells and NKT cells to naïve conventional T cells. The change in the 
balance of T cell subsets is best explained by their differential resistance to radiation induced 
cell death due to differential expression of the anti-apoptotic protein, Bcl-2, as reported 
previously (Yao et al., 2009). Nador et al, 2010 showed thatp53-/- mice had no change in the 
balance after TLI. T cell proliferation and thymic generation of T cells play a minimal role 
whereas the p53/Bcl-2 apoptotic pathway plays the dominant role in the changes (Yao et al, 
2009). The considerable resistance of Treg cells to apoptosis induced by ATS as compared to 
conventional T cells has been reported to be due to high levels of expression of the anti-
apoptotic protein, BCLXL (Ninamimura et al, 2006). It is of interest that the altered balance 
of T cell subsets favoring Treg and NKT cells returned to normal about 6 weeks after 
conditioning, and by that time the stable mixed chimeras are tolerant to the heart allografts 
due to clonal deletion (Higuchi et al, 2002).  
The relationship between NKT cells and Tregs in responses to alloantigens has been 
reported recently (Pillai et al, 2009). Naïve but not memory phenotype CD4+ T cells from 
untreated mice show alloreactivity in the MLR, and alloreactivity by conventional T cells in 
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the MLR is suppressed by Treg cells at a 1:1 ratio (Dutt et al., 2007; Schiopu,  A. & Wood, 
2008). The changed ratio of these cells on day 1 was likely to have prevented the hosts from 
rejecting bone marrow and heart allografts acutely. In another experiment, the ability of 
naïve and memory phenotype T cells from untreated BALB/c mice to reject C57BL/6 heart 
allografts was compared by transferring equal numbers of sorted cells to immunodeficient 
RAG-2-/- BALB/ c hosts bearing the grafts. Whereas the naïve cell injection resulted in 
rejection of all grafts, the memory phenotype cell injection obtained from donors that had 
not been exposed to alloantigens resulted in no rejection over a 100-day observation period. 
In conclusion, the TLI and ATS tolerance induction model requires both regulatory NKT 
cells and Tregs for graft acceptance. Tolerance is promoted by profound but transient 
changes in the balance of regulatory and naive T cells of host origin favoring the regulatory 
cells. (Nador et al, 2010) 
4. Irradiation and self-reactive immune response 
CD4 regulatory T cells (Tregs) are the main effectors of immunological tolerance in adult 
life. Several studies have indicated that quantitative and qualitative abnormalities of 
regulatory Tregs contribute to the pathogenesis of autoimmune diseases as collagen-
induced disease arthritis (CIA) (Morgan et al, 2003; Morgan et al, 2005) and in a spontaneous 
model of Rheumatoid Arthritis (RA).(Sakaguchi et al, 2003)  There is evidence that the local 
proinflammatory environment is fundamental in imparting a Treg defect, because the 
treatment with anti-tumour necrosis factor (TNF)ǂ may restore their function by generating 
transforming growth factor (TGF)ǃ producing Tregs.(Nadkarmi et al, 2007). Therefore, 
generating functionally effective Tregs may provide an effective approach for the treatment 
of collagen-induced disease. 
The adoptive transfer of Tregs can be efficacious in the treatment of autoimmune diseases in 
preclinical models,(Tang Q, 2004) but the major limitation of such a strategy is that, in order 
to obtain a dose sufficient for clinical use, Tregs need to be expanded in vitro with 
implications on their functionality (Hoffman et al, 2009). An alternative strategy is to 
increase the number of Tregs by exploiting the selective advantage of Tregs over 
conventional T cells during homeostatic reconstitution following cell ablative treatments 
(Cox et al., 2005; Nadal et al., 2007).  It was previously reported that even non-myeloablative 
doses of irradiation are sufficient to determine a selective retention/expansion of Tregs 
capable of producing an immunosuppressive activity against donor haematopoietic 
antigens, thus facilitating their engraftment (Weng et al, 2007). Therefore, one very possible 
hypothesis is that partial myeloablation could also generate the conditions to control 
autoimmune diseases. 
Myeloablative regimens have successfully been used for the treatment of severe forms of 
autoimmune arthritis (Dazzi et al.; 2007) whereby the consequent haematopoietic 
reconstitution is associated with a comprehensive renewal of the T cell repertoire (Murano 
et al, 2005). The major drawback of these approaches is toxicity. Mild myeloablation appears 
to be sufficient to modulate pathogenic immune responses and produce beneficial effects on 
CIA (Nakatsukasa et al, 2008) but the mechanisms remain to be clarified.  
Weng et al., 2010 demonstrated that low-dose irradiation ameliorates CIA at the time of 
disease induction and if used when clinical signs of the disease are detectable. They 
established a causative relationship between the therapeutic efficacy of irradiation and Treg 
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mediated tolerance. Irradiation induced immune tolerance to the immunizing collagen 
through modalities that require the presence of Tregs. The therapeutic activity is associated 
with the development of Treg immunosuppressive activity and the in vivo depletion of 
Tregs prevents the beneficial effects of irradiation. 
Tregs selectively survive myeloablative regimens and undergo a marked expansion while 
retaining their functional activity (Bayer et al., 2009). The same mechanisms might account 
for the therapeutic efficacy of autologous BM transplantation in autoimmune arthritis 
(Roord et al., 2008). In a proteoglycan-induced arthritis, the conditioning of recipient mice 
with a lethal irradiation dose (7.5 cGy) and subsequent syngeneic BM transplantation 
significantly reduced the severity of arthritis. This study observed an increment in the 
proportion of CD4CD25 T cells and the clinical improvement was prevented if recipient 
mice received anti-CD25 depleting antibodies 1 week after the transplant. In contrast to 
other results, the investigators did not observe any effect if anti-CD25 antibodies were given 
on the day of the transplant. The disparity should be ascribed to the different intensity of the 
conditioning regimen (7.5 cGy vs 4 cGy) that delayed Treg homeostatic reconstitution as 
demonstrated by the delayed peak of Treg expansion following the myeloablative dose 
(Bayer et al, 2009).  
The transient nature of the therapeutic effect induced by low-dose irradiation in the CIA 
model can result from the contribution of various factors. Firstly, the Tregs that are 
proportionally expanded following the non-myeloablative regimen are of recipient origin 
and, because of the rapid expansion kinetics, of the memory type. Their effect could be less 
durable and/or less potent than the naive Tregs that are generated at a later stage during 
the haematopoietic reconstitution following full myeloablation (Roord et al., 2008).  
However, to our knowledge there is no evidence of such at difference in the activity of 
different Treg subtypes and it is more likely that the magnitude of myeloablation differently 
influences the duration and thus the efficacy of the Tregs proportional increment (Weng et 
al., 2007; Laylor et al, 2005). The quantization of CD4CD25FoxP3+ following low-dose 
irradiation indicated that the percentage of Tregs increased at 12 days and, although less so, 
also remained elevated a week later. However, when we enumerated the absolute values, 
the numbers of CD4CD25FoxP3+ were much reduced as compared to CIA controls. Since 
the absolute number of CD4FoxP3−T cells, which contain the fraction responsible for 
mediating the disease, was equally reduced, it is the resulting change in the ratio between 
effectors and Tregs that should account for the therapeutic effect. The characterization of the 
effector cells in treated mice suggests that the dose of irradiation used did not affect the 
proportion of IL17 producing T cells. Since IL17 has been suggested to play an important 
role in RA and CIA (Fugimoto et al, 2008), it appears that neither irradiation nor the 
proportional Treg expansion is sufficient to interfere with IL17 production. Although this 
could justify the incomplete therapeutic effect, the levels of T helper 17 cells (Th17) in 
peripheral lymphoid tissues do not correlate with their levels in the injured tissues. It has 
been reported that anti-TNFǂ treatment, despite its ability to prevent Th17 in the joints 
increases their numbers in draining LNs.(Notley et al., 2008) We also observed that the 
numbers of IFNǄ-producing cells are reduced in the irradiated animals. While reducing the 
inflammatory activity, the inhibition of IFNǄ production also limits the potential to convert 
effector to FoxP3+ cells.(Xiao et al., 2008) The interpretation of the data is complicated by the 
fact that the pathogenic or protective effects of these cytokines are dependent on the timing 
of their production.(Lohr et al., 2006) The evidence provided the rationale to exploit the 
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selective Treg activation induced by partial immunoablation for the treatment of 
autoimmune diseases. Further studies are however warranted to improve the duration of 
the therapeutic efficacy (Weng et al., 2010). 
5. Radiotherapy and immunomodulation in cancer 
Radiation is commonly used as a method of decreasing lymphocyte numbers via 
cytotoxicity for the purpose of bone marrow transplantation (BMT). CD25þCD4þ regulatory 
T cells (Treg) comprise 5–10% of the circulating CD4þ T cell population and suppress 
immune responses. A large body of experimental data suggests an essential role played by 
these cells in self-tolerance, transplantation, allergy and tumor/microbial immunity (Wing 
et al. 2006). Currently, many investigators are pursuing strategies to modulate the function 
or the number of Treg, which may offer a means to regulate host immunity for therapeutic 
effect in autoimmune diseases and cancers (Zou 2006). However, previous investigators 
have also suggested that low-dose whole-body irradiation (LTBI) results in immune 
enhancement in the treatment of chronic lymphocytic leukemia (CLL) and lymphoma 
(Safwat 2000a, 2000b). Accumulating evidence shows that irradiation influences the 
phenotype and function of immune cells (Cao et al. 2004, 2009, Reuben et al. 2004, Merrick et 
al. 2005). For example, Cao et al, showed that irradiation inhibited proliferation and 
suppressive ability of Treg with dose-dependent decrease of FOXP3 expression (Cao et al. 
2009). A differential radiosensitivity and apoptosis-related proteins expression exist at 
varying doses of  radiation between human Treg and effector T cells.   LTBI is successful in 
inducing long-term remissions and has been shown to be as effective as the chemotherapy 
to which it has been compared in lymphoma (Safwat 2000a). However, the mechanism of 
this effect is unknown. The efficacy of LTBI could be partly attributed to a radiation-induced 
immune enhancement rather than to direct killing of tumor cells by radiation. This type of 
immune enhancement could be induced by two mechanisms: a differential elimination of 
the suppressive T subset of lymphocytes or an augmentation of the immune response 
through direct and/or indirect stimulation of T lymphocytes. RT can also theoretically 
enhance anti-tumor immunity via increasing the expression of tumor-associated antigens, 
inducing immune-mediated targeting of the tumor stroma, and diminishing regulatory T 
cell activity. Recent evidence suggests that RT may also activate effectors of innate 
immunity through Toll-like receptor (TLR)-dependent mechanisms, thereby augmenting the 
adaptive immune response to cancer (Roses et al. 2008). Thus RT can be better-characterized 
as having immunomodulatory properties that can allow its use as adjunct to 
immunotherapy (McBride et al. 2004).  
6. Enhancement of antitumor effectors mechanisms 
The efficacy of radiation therapy in the treatment of many tumor types is well established. 
While radiation induced tumor regression is largely the result of directed damage to 
radiosensitive tumor cells, evidence points to a number of additional immune-mediated 
mechanisms. Suppressor populations of T cells may be more radiosensitive than their 
effector counterparts and, conversely, tumor-specific effector T cells may be relatively radio-
resistant (North, 1986; Dunn and North, 1991). This notion, as it relates to contemporary 
definitions of regulatory T cells (Tregs), has not been extensively explored. However, one 
recent study implicated Treg depletion in the enhanced efficacy of adoptive T-cell 
www.intechopen.com
 
Immunosuppression – Role in Health and Diseases 
 
396 
immunotherapy for transplanted melanomas following whole-body irradiation in a murine 
model (Antony et al., 2005). Enhanced functionality of adoptively transferred T cells 
following radiation induced  lympho-depletion has also been linked to increased availability 
of homeostatic cytokines (Wrzesinski et al., 2007). A number of studies have measured the 
effects of low-dose total-body irradiation on the relative size of T-cell subpopulations and 
expression of cytokines associated with T-cell activation. In one report, low dose irradiation 
following transplantation of a hepatoma cell line in a rat model resulted in an increased 
proportion of CD8-positive splenocytes, increased numbers of tumor infiltrating 
lymphocytes, increased TNF-a and IFN-g expression and decreased TGF-b expression This 
response correlated with a reduction in metastases (Hashimoto  et  al., 1999). Another study 
demonstrated an increased CD4:CD8 T cell ratio, and decreased expression of TGF-b and 
VEGF following low-dose total body-irradiation, which correlated with delayed tumor 
growth in mice transplanted with the Lewis lung carcinoma cell line (Miller et al., 2003). The 
so-called ‘abscopal effect’, whereby radiation results in reduced tumor growth outside the 
direct radiation field, suggests radiation-induced immune-mediated mechanisms. The fact 
that this effect may be enhanced with Fms-like tyrosine kinase receptor 3 ligand (Flt-3L), a 
stem cell mobilizing factor that augments the number of circulating DC precursors, in 
immunocompetent mice and abrogated in T-cell-deficient mice lends additional support to 
this contention (Demaria et al., 2004). 
7. Stromal effects 
Radiation may induce immune-mediated targeting of tumor stroma. Antigen released 
following tumor irradiation may be presented by stromal cells for subsequent destruction by 
CTLs. This mechanism was recently demonstrated by Zhang et al. (2007) in experiments 
utilizing immunodeficient mice given tumor transplants. Only the combination of 
irradiation and adoptive transfer of CTLs resulted in tumor regression. This regression 
correlated with increased expression of tumor-specific peptide-MHC complexes as 
delineated using a tumor antigen/MHC complex-specific TCR tetramer. Direct effects of 
radiation on the stroma may play a role in enhancing immune-mediated tumor regression as 
well. Induced modulation of the expression of adhesion molecules, such as accumulation of 
P-selectin in the lumen of tumor vasculature, may enhance infiltration of immune effectors 
into the tumor stroma (Hallahan et al., 1998; Hallahan and Virudachalam, 1999). 
Enhancement of tumor antigen recognition Induction of antitumor immunity by radiation 
may result from enhanced tumor antigen recognition. Irradiation induces tumor cell 
apoptosis, or necrosis secondary to vascular injury (Acker et al., 1998). Subsequent 
phagocytosis of apoptotic bodies by DCs and initiation of antitumor T-cell responses 
through cross presentation may ensue if DC maturation signals are concomitantly present. 
A number of studies have suggested that necrosis, but not apoptosis, is associated with DC 
maturation signals (Basu et al., 2000; Sauter et al., 2000) However, more recently evidence 
that some apoptotic pathways do induce DC maturation and antitumor immunity has 
emerged (Scheffer et al., 2003). Sublethal irradiation of tumors may also result in enhanced 
expression of surface molecules recognized or targeted by immune effectors, as is suggested 
by studies demonstrating increased expression of the MHC class I antigen, H-2D, by 
melanoma cells (Hauser  et al., 1993) and tumor associated antigens including 
carcinoembryonic antigen by gastric adenocarcinoma cells (Hareyama et al., 1991). Increased 
expression of the death receptor Fas following radiation has also been demonstrated in a 
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transgenic carcinoembryonic antigen-expressing tumor model and associated with greater 
susceptibility to CTL mediated tumor cell lysis (Chakraborty et al., 2003). Combining 
immunotherapy and radiation building upon the hypothesis that radiation can enhance 
anti-tumor immunity, investigators have begun to combine radiation therapy with 
immunotherapies as was recently reviewed (Demaria et al., 2005a). Generally, such efforts 
employ radiation to induce tumor cell apoptosis or necrosis with resultant antigen release 
for subsequent presentation by DCs. Several investigators have studied combinations of 
intra-tumoral or peri-tumoral DC administration (Nikitina and), or administration of Flt-3L 
(Chakravarty et al., 1999, 2006; Demaria et al., 2004) combined with irradiation, yielding 
promising results. Administration of a recombinant viral vaccine-expressing tumor-
associated antigen(s) and costimulatory molecules in combination with tumor irradiation 
may capitalize on the capacity of radiation to enhance immune recognition of antigen-
expressing tumor cells. Such an effect was recently demonstrated and linked to radiation 
induced up regulation of Fas on tumor cells (Chakraborty et al., 2004). A number of 
investigators have explored combinations of cytokine therapy and irradiation; studied 
cytokines include IL-3 (Chiang et al., 2000), IL-12 (Seetharam et al., 1999; Lohr et al., 2000) 
and TNFa (Weichselbaum  et al., 1994). Local radiation therapy in combination with CTLA-4 
blockade is an additional novel approach for overcoming mechanisms of tumor tolerance. 
This combination was recently demonstrated to induce anti-tumor CD8 T cells in a poorly 
immunogenic murine adenocarcinoma model, whereas CTLA-4 blockade alone did not 
(Demaria et al., 2005b). Collectively, these studies encourage optimism regarding the 
potential of combined immunotherapy and radiotherapy. 
The  ‘innate’ components of the mammalian immune system has been reviewed and new 
concepts introduced; the discovery of Toll-like receptors (TLRs) is a notable example. These 
receptors recognize highly conserved molecular patterns common to pathogens, termed 
pathogen-associated molecular patterns (Janeway and Medzhitov, 2002). Examples of 
pathogen-associated molecular patterns and corresponding TLRs include:doublestranded 
RNA, which is recognized by TLR3 (Alexopoulou et al., 2001), Lipopolysaccharide (LPS), 
which is recognized by TLR4 (Poltorak et al., 1998) and many others (Roses et al., 2008).   
An extensive investigation into the molecular basis of TLR function has been undertaken in 
recent years (Akira and Takeda, 2004). Though considerable overlap exists between 
implicated pathways, signaling through the various TLRs may initiate discreet downstream 
molecular events. Most TLRs act through the myeloid differentiation primary response 
protein 88 (MyD88) and tumor necrosis factor receptor-associated factor 6 to activate nuclear 
factor kB (NF-kB) and mitogen-activated protein kinases and induce gene transcription. At 
the cellular level, TLR binding results not only in the activation of effectors of innate 
immunity, but also in the induction of adaptive responses. Ligation of TLRs expressed by 
antigen presenting cells may result in the expression of co-stimulatory molecules (for 
example, CD80 and CD86) and cytokines (for example, IL-6 and IL-12) (Macagno et al., 
2007). Moreover, TLR-primed dendritic cells induce antigen-specific high avidity CD8 (Xu et 
al., 2003, 2006) and type-I polarized CD4 T-cell responses (Wesa et al., 2007). These findings 
have provided a foundation for immunotherapeutic strategies targeting tumor-associated 
antigens for the treatment of malignancies 
Through the induction of antigen-presenting cell maturation and secretion of 
proinflammatory chemokines and cytokines, TLRs provide a link between innate and 
adaptive immunity, which may be exploited to induce robust immune responses against 
specific antigens, the therapeutic potential of TLR-targeted therapies. Conversely, TLR-
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targeted therapy may enhance subsequent responses to chemotherapy. Such combinations 
have been explored in a number of preclinical studies, sometimes with promising results 
(Lake and Robinson, 2005; Bourquin et al., 2006; Shi et al., 2007). While radiation therapy has 
not been explored as extensively, it too is emerging as a potentially powerful tool when 
combined with immunotherapies. 
8. Radiation-induced TLR signaling  
Investigations into the function TLRs have provided mechanistic insight into the actions of 
several established cancer therapies. Recent evidence suggests that TLR-dependent 
mechanisms contribute to the therapeutic effects of radiation as well. It has been widely 
hypothesized that tumor irradiation activates effectors of innate immunity through the 
induction of tumor cell apoptosis and the release of endogenous TLR agonists. The 
observation that such ubiquitous factors heat-shock proteins and uric acid can act through 
TLRs and induce DC maturation (Gallucci et al., 1999) supports this mechanism as does the 
demonstration that immature DCs, when administered into irradiated tumors, induce 
antitumor immunity (Kim et al., 2004).Most recently, the high-mobility-group box 1 alarmin 
protein, released by dying tumor cells, was shown to act on TLR4 expressed by DCs. 
Moreover, binding of TLR4 was demonstrated to increase the efficiency of tumor antigen 
processing and presentation (Apetoh et al., 2007). TLR dependent mechanisms may play a 
role in systemic therapies as well. Whole body irradiation was recently shown to increase 
bacterial translocation and circulating levels of the TLR 4 agonist lipopolysaccharide. This 
phenomenon was associated with enhanced anti-tumor immunity in an adoptive transfer 
model (Paulos et al., 2007). When considered together, such evidence provides a strong 
rationale for the use of radiation therapy as an immune intervention; a paradigm shift from 
the traditional view of radiation therapy as a cytotoxic therapy. The capacity of radiation to 
elicit the expression of TLR ligands systemically after gastrointestinal tract irradiation, or 
locally after tumor irradiation, may prove valuable in conjunction with other 
immunotherapies. 
Potentiating anti-tumor immunity with radiation therapy and TLR agonists 
Few investigators have directly studied the combination of radiation and TLR-targeted 
therapies; this despite recognition that the therapeutic effects of radiation maybe dependent 
upon TLR signaling. Mason et al. (2005) recently demonstrated a markedly enhanced tumor 
response to radiation therapy following peri- and intratumoral injections of the TLR agonist, 
CpG, in a murine fibrosarcoma model (Milas et al., 2004). In light of the recently elucidated 
role of TLRs in radiation induced responses, this effect may reflect synergy at the level of 
TLR signaling. Further investigations are required to determine the applicability of such 
approaches but potential implications of these findings are broad. TLR-targeted therapy 
may sensitize a wide range of tumor types to radiation therapy and result in a reduction of 
the radiation dose necessary to achieve a therapeutic effect. Such approaches may become 
increasingly important as new TLR-targeted therapies emerge. 
9. Conclusions 
Definitely, radiotherapy has been seen now as a immunomodulatory treatment. Many 
concepts has been changing during the past few years. A role for novel neoadjuvant 
immunotherapies is emerging and will result in opportunities to study their interplay with 
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conventional treatments, such as chemotherapy and radiation and immunosuppressive 
drugs. Radiation therapy may be an important adjunct to immunotherapies with the 
potential to enhance the antigenicity of tumors and promote stromal targeting. Perhaps 
more importantly, radiation therapy may activate effectors of innate immunity through 
TLR-dependent mechanisms. The relative contributions of these distinct radiation-induced 
mechanisms remain unclear. As we learn more about the immune-mediated mechanisms  
we will be better able to utilize these modalities and emerging immunotherapies in 
combination (Roses et al, 2008). 
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